iRhythm Holdings (IRTC) Osake Kurssi
iRhythm Holdings Kurssi
Liikevaihto on kasvanut 38,2 % vuodessa viimeisten 12 vuoden aikana 747,14 M USD:een. iRhythm Holdings,n nettomarginaali on nyt −6,0 %, noussut −31,4 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 168,00 USD, eli yli nykyhintaa 32,9 %. 22 analyytikosta 21 suosittaa ostoa — kokonaiskonsensus on Osta.
iRhythm Holdings, osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
iRhythm Holdings, liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset iRhythm Holdings, -osakkeesta
Some significant milestones achieved by iRhythm Technologies Inc include being listed on the NASDAQ in 2016, receiving FDA approval for their Zio XT patch in 2011, and launching the Zio patch in Europe in 2013. The company has also collaborated with various institutions and organizations to conduct clinical studies and trials. In 2020, iRhythm Technologies Inc introduced the Zio AT wearable patch, expanding its product offerings. These achievements demonstrate iRhythm Technologies Inc's commitment to revolutionizing cardiac arrhythmia detection through innovative and reliable solutions.
iRhythm Technologies Inc primarily operates in the United States.
The business model of iRhythm Technologies Inc revolves around providing innovative solutions for cardiac arrhythmia diagnosis. As a leading digital healthcare company, iRhythm focuses on developing and commercializing unique wearable biosensor technology. By leveraging their proprietary data analytics platform, Zio, iRhythm aims to transform the way cardiac arrhythmias are detected and managed. The Zio XT Patch, their flagship product, offers patients a convenient and continuous monitoring experience, facilitating early detection and accurate diagnosis of irregular heart rhythms. With a patient-centered approach, iRhythm Technologies Inc strives to improve patient outcomes, reduce healthcare costs, and enhance the overall quality of cardiac care.
iRhythm Technologies Inc is primarily active in the healthcare and medical technology industries.
iRhythm Technologies Inc faces competition from various players in the market. Some of its main competitors include BioTelemetry Inc, CardioNet Inc, and ZioPatch. These companies also operate in the healthcare technology sector, providing remote cardiac monitoring solutions similar to iRhythm. With its innovative products and services, iRhythm Technologies Inc strives to maintain a competitive edge and solidify its position in the market.
iRhythm Technologies Inc is a leading digital healthcare company that focuses on delivering personalized, patient-centered care. Founded in 2006, the company developed the Zio XT Patch, a wearable biosensor that continuously monitors heart rhythms in order to detect and diagnose cardiac arrhythmias. With its advanced AI-powered algorithms and cloud-based platform, iRhythm Technologies Inc provides physicians with actionable insights to facilitate accurate diagnoses and develop effective treatment plans. The company has revolutionized remote cardiac monitoring and has gained significant recognition for its innovative approach to improving patient outcomes. iRhythm Technologies Inc is committed to advancing cardiac care through cutting-edge technology and data-driven solutions.
iRhythm Technologies Inc represents a commitment to improving patient care through innovative healthcare solutions. The company values include technological advancement, patient-centric care, and use of data-driven approaches. iRhythm's corporate philosophy is centered around leveraging wearable medical devices and digital health solutions to revolutionize how cardiac arrhythmias are diagnosed and managed. By combining cutting-edge technology with a focus on patient outcomes, iRhythm aims to enhance cardiac care and empower both patients and healthcare providers. With its dedication to innovation and improving cardiac health, iRhythm Technologies Inc has become a leader in the digital healthcare industry.
Analyytikot asettavat tällä hetkellä iRhythm Holdings,-osakkeelle keskimääräisen tavoitehinnan 175,89 USD (mediaani: 168,00 USD), mikä merkitsee +39,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 22 analyytikkoarvioon.
22 analyytikkoa arvioi tällä hetkellä iRhythm Holdings,-osaketta: 21 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat iRhythm Holdings,-yhtiöltä 890,60 M USD liikevaihtoa ja −0,21 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla iRhythm Holdings,-osake noteerataan hintaan 112,90 EUR (126,37 USD).
iRhythm Holdings,-osake (IRTC) on listattuna 5 pörssissä, muun muassa: NASDAQ (IRTC), London (0A7L.L), Frankfurt (I25.F), München (I25.MU), Düsseldorf (I25.DU).
iRhythm Technologies Inc is a leading MiCoast company (Mobile Cardiac Outpatient Telemetry) based in San Francisco, California. The company's business model primarily consists of developing and manufacturing diagnostic monitoring systems for detecting heart rhythm disorders. iRhythm's products and services are used by doctors and clinics around the world to diagnose and treat patients with heart rhythm disorders. iRhythm is known for its patented Zio® XT technology, a portable EKG monitoring device that allows doctors and clinics to monitor patients' heart function over an extended period to identify possible heart rhythm disorders. The Zio XT is portable, discreet, and can be worn for up to 14 days. The device can be easily and quickly applied by medical professionals and comfortably worn by the patient. iRhythm's business model consists of several divisions that aim to develop and market innovative medical solutions. The three main divisions of iRhythm are: 1. Devices and accessories: iRhythm produces a variety of medical devices and accessories, including the Zio XT, Zio AT (for ambulatory monitoring), and other diagnostic tools. 2. Data analysis and interpretation: Capturing continuous heart rate data over a longer period can be extremely labor-intensive. For this reason, iRhythm offers an analysis and interpretation service to make life easier for professionals. 3. Training and support: iRhythm provides training and support services to help practitioners and patients better understand the benefits of diagnostic monitoring systems. iRhythm aims to improve the quality and efficiency of the diagnosis and treatment of heart rhythm disorders while drastically reducing costs. As it is a chronic condition, recurring doctor visits and diagnostic tests can be extremely expensive. iRhythm seeks to solve this problem by providing a solution that allows the patient to be monitored in their normal environment without requiring countless doctor visits. In the past, iRhythm has partnered with various investors and clinics to bring to market and promote the Zio XT technology. The company works closely with medical professionals and institutions, utilizing its expertise to ensure high-quality and effective diagnostics. In the past, iRhythm has focused primarily on selling its products in the United States. However, the company is now expanding globally and currently expanding its market in Europe and Asia. Overall, iRhythm has established itself as a successful company aiming to improve the diagnosis and treatment options for heart disease. The company continues to pursue its mission of providing innovative products and services to improve the lives of people with heart disease.
odotettu liikevaihto iRhythm Holdings, on 890,60 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto iRhythm Holdings, on −7,09 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
iRhythm Holdings,:n hinta-voitto-suhde (P/E) on tällä hetkellä −594,23. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan iRhythm Holdings,-osakkeen arvostusta.
iRhythm Holdings,:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,73. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii iRhythm Holdings,-osakkeen arvostuskennuslukuna.
iRhythm Holdings,:n Eulpool-laatuscore on 6/10.
iRhythm Holdings,:n ISIN on US4500561067. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
iRhythm Holdings,:n WKN on A2ATTS. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
iRhythm Holdings,:n ticker on IRTC. Tämä pörssinoteeraus käytetään iRhythm Holdings,-osakkeiden kauppaan pörssissä.
iRhythm Holdings, osake
iRhythm Holdings, vertaisryhmä
iRhythm Holdings, Ticker
iRhythm Holdings, FIGI
Kaikki tunnusluvut ja syvällinen analyysi iRhythm Holdings,:sta
Meidän osakeanalyysimme iRhythm Holdings,-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut iRhythm Holdings,:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: